{"id":220204,"date":"2026-08-27T10:41:48","date_gmt":"2026-08-27T05:11:48","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=220204"},"modified":"2026-08-27T10:41:50","modified_gmt":"2026-08-27T05:11:50","slug":"animal-health-veterinary-pharmaceutical-stocks-india-future-roadmaps-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/animal-health-veterinary-pharmaceutical-stocks-india-future-roadmaps-2026\/","title":{"rendered":"Animal Health and Veterinary Pharmaceutical Stocks in India with Strong Future Roadmaps as Livestock Productivity Focus, Export Growth, and Companion Animal Care Expansion Drive Structural Demand"},"content":{"rendered":"
<\/div>\n

India animal health market FY26: Rs 10,000 Cr+. Sequent Scientific MCap Rs 12,238 Cr, PE 45.83 above sector 37.20, ROE 7.07%. Thin listed pure-play universe. CAUTION: single dominant listed player. 5 picks: SEQUENT, VIRBAC(unlisted ref), VENKYS(adjacent ref), ZYDUSANIMAL(unlisted ref), INDIANIMMUNO(unlisted ref).<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Sequent Scientific is India’s primary listed animal health and veterinary pharmaceutical stock, manufacturing veterinary APIs and formulations for global markets, trading at PE 45.83, above the animal health and veterinary pharmaceutical stocks sector PE of 37.20, with a modest ROE of 7.07%. India’s animal health sector, historically served largely through unlisted or subsidiary structures of larger pharmaceutical companies, benefits from growing livestock productivity focus, export demand for veterinary pharmaceuticals, and expanding companion animal care in urban India.<\/p>\n<\/div>\n

India’s animal health sector serves both the large livestock population (requiring productivity-focused veterinary medicine for dairy cattle, poultry, and other farm animals) and a growing companion animal care segment in urban India, as pet ownership rises alongside increasing willingness to spend on pet healthcare. Export opportunities exist for Indian veterinary pharmaceutical manufacturers given India’s broader generic pharmaceutical manufacturing expertise extending naturally to veterinary applications.<\/p>\n

For investors, this thin sector centers on Sequent Scientific as the primary viable listed option. All data is as of 26 August 2026.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n